N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,392 Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)
Chest Pain · Acute Coronary Syndrome · Acute Myocardial Infarction
Primary: Rates of Major Cardiac Events (AMI or Cardiac Death) Within 30 Days — 0; 0; 0; 10 Participants
N/A N=25 WATCHMAN FLX™ CT Study
The Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation
Primary: Number of Participants With Any Hypoattenuated Thickening (HAT) on the Surface of the Device — 5; 3; 2 Participants
N/A N=864,080 CT DOSE Collaboratory
Ionizing Radiation Exposure · Quality Improvement
Primary: Change in Mean Effective Dose (ED) — -0.13; -0.81; -0.14; -0.26 Millisieverts (mSv)
N/A N=150 Chronic Total Occlusion Percutaneous Coronary Intervention Study
Chronic Total Occlusion · Ischemic Heart Disease · Chronic Total Occlusion of Coronary Artery
Primary: Number of Participants With Procedure Success — 121 Participants
Phase 2 N=45 CTx-1301 Comparative Bioavailability Study
ADHD
Primary: Cmax — 3138.41; 2874.52; 0.92; 23884.13 pg/mL
N/A N=10,003 PROspective Multicenter Imaging Study for Evaluation of Chest Pain
Chest Pain
Primary: Time to Primary Endpoint — 1.0; 1.1; 1.2; 1.4 Percentage of participants with an event
Phase 3 N=1,000 Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography
Acute Coronary Syndrome · Myocardial Infarction · Unstable Angina Pectoris
Primary: Length of Hospital Stay — 23.2; 30.8 hours
Phase 2 N=200 EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients
Cystic Fibrosis
Primary: Difference From Placebo in Absolute Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted (ppFEV1) — -1.30; -3.76; -2.53; -2.69 FEV1 percent…
N/A N=100 CTEPH Identification an Standard Computerised Tomography Pulmonary Angiography in Pulmonary Embolism Patients
CTEPH · Pulmonary Embolism · Early Diagnosis
Primary: To Identify the Accuracy of Routine CTPA for the Distinction of CTEPH From Acute PE. — 70; 70 Sensitivity
N/A N=102 Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus
Atrial Fibrillation
Primary: Time to Imaging — 28.1; 7.1 hours
N/A N=285 Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography
Coronary Artery Disease
Primary: Percentage of Participants With Diagnostic Accuracy of CCTA Plus FFRCT and CCTA Alone — 73; 64 percentage of participants
N/A N=1,748 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA
Acute Coronary Syndrome
Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants
N/A N=88 Chronic Total Occlusion Crossing With the Wildcat Catheter
Peripheral Arterial Disease
Primary: Major Adverse Events — 4 participants
Phase 4 N=398 CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
Patient Adherence · HIV Seronegativity
Primary: Adherence to PrEP — 85.6; 91.7; 81.6; 83.4 % participants with > 719 fmol/punch
N/A N=34 Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study
Aortic Aneurysm · Contrast Induced Nephropathy · Aortic and Arterial Anomalies
Primary: Ascending Sinotubular Junction Measurement — 246.4; 287.5 Hounsfield units
N/A N=276 HeartFlowNXT - HeartFlow Analysis of Coronary Blood Flow Using Coronary CT Angiography
Coronary Artery Disease
Primary: AUC of FFRct Versus Coronary CTA for Demonstration of Ischemia (≤0.80) on a Per-patient Basis — .90; .81 probablility
N/A N=1,216 Role of On-site CT-derived FFR in the Management of Suspect CAD Patients
Coronary Artery Disease
Primary: Number of Participants With ICA Without Obstructive CAD or Intervention — 421; 483; 119; 223 Participants — p=0.05
N/A N=127 Observational Registry Characterizing the CTAG Device With ACTIVE CONTROL
Thoracic Diseases
Primary: Number of Subjects With Procedural Technical Success — 123 Participants
N/A N=900 Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
Coronary Artery Disease
Primary: Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina — 34; 28 Participants
Phase 3 N=33 Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)
Coronary Computed Tomographic Angiography
Primary: Contrast to Noise Ratio — 18.6; 20.5 CNR
Phase 2 N=7 CX-8998 for Absence Seizures
Epilepsy
Primary: Change From Baseline to End of Treatment in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) — 3.50 msec
N/A N=586 The Value of CT Fractional Flow Reserve
Angina, Stable Chest Pain
Primary: Comparison of CCTA Alone to FFR-CT After CCTA — 90.97; 92.73; 22.86; 69.71 percent — p=1.00
N/A N=22 QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)
Atrial Arrhythmia · QT Interval, Variation in · Arrhythmias, Cardiac
Primary: QT Intervals During Antiarrhythmic Loading Hospitalization — 21.8 milliseconds
Phase 3 N=103 Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
ADHD · Attention Deficit Hyperactivity Disorder · ADHD - Combined Type
Primary: The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Attention Deficit Hyperactivity Disorder Rating Scale 5 (ADHD-RS-5)…
N/A N=100 Chronic Total Occlusion Crossing With the Ocelot System - CONNECT II
Total Atherosclerotic Occlusion of Femoral Artery
Primary: Primary Safety Endpoint — 2 Percent of participants
Phase 3 N=1,000 Trial to Assess Chelation Therapy 2
Diabetes · Myocardial Infarction
Primary: Primary Composite Outcome — 85; 89; 90; 86 Participants
Phase 4 N=150 Thoracoabdominal Arortic CTA Study
Thoracic Aortic Aneurysm
Primary: Radiation Dose — 35.1; 25.4; 25.5 mSv
Phase 3 N=1,068 Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis
Complicated Urinary Tract Infection · Pyelonephritis
Primary: The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the…
N/A N=110 TX2® Low Profile TAA Endovascular Graft
Aortic Aneurysm · Penetrating Ulcer · Vascular Disease
Primary: Patients With Major Adverse Events (MAE) — 2; 3 participants — p=< 0.001